At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
adeno-associated virus vector AAV- CNGA3biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3
In Brief
A Phase 2 clinical trial evaluating adeno-associated virus vector AAV- CNGA3 for Achromatopsia. Completed, enrolled 11 participants across 2 sites in 2 countries.
Detailed Summary
A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAchromatopsia
CountriesUnited Kingdom, United States
CollaboratorsJanssen Research & Development, LLC
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartAug 2019
Primary CompletionJun 2021
TodayJul 2026
First PostedNov 29, 2018
Enrollment StartAug 12, 2019
Primary CompletionJun 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago
Interventions
adeno-associated virus vector AAV- CNGA3biological
Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene